Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1191 results
May 2022
-
Media ReleaseSandoz appoints new Board representative to global AMR Industry AllianceDr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life…
-
Media ReleaseNovartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditionsPositive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these…
-
Media ReleaseNovartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancerLatest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new…
-
Media ReleaseNovartis provides update on production of radioligand therapy medicinesNovartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of…
-
Media ReleaseNovartis receives European Commission approval for Jakavi® to be the first post-steroid treatment for acute and chronic graft-versus-host diseaseJakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GvHD)1,2 In clinical…
-
Media ReleaseNew Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patientsWith further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for…
-
Media ReleaseNovartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphomaKymriah offers patients in Europe with advanced follicular lymphoma a potentially definitive, single infusion CAR-T cell therapy with a remarkable safety profile Approval based on the Phase II…
April 2022
-
Media ReleaseNovartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III studyRATIONALE 306 trial met primary endpoint at interim analysis, demonstrating tislelizumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with…
-
Key ReleaseNovartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen WachstumsaussichtenAd-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im ersten Quartal um +5% (kWk1, +1% USD), das operative Kernergebnis wuchs um +9% (kWk, +3% USD) Innovative Medicines (IM) steigerte…
-
Key ReleaseNovartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlookAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core…
-
Key ReleaseNovartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen termeAnnonce événementielle selon l’art. 53 RC Chiffre d’affaires du T1 en hausse de +5% (tcc1, +1% USD) et résultat opérationnel core en progression de 9% (tcc, +3% USD) Innovative Medicines (IM):…
-
Media ReleaseNovartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancerOpinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with…
Pagination
- ‹ Previous page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- …
- 100
- › Next page